D-Luciferin for Reliable Luciferase Assays
2026-10-01
Learn how D-Luciferin, SKU B6040, supports more interpretable ATP-dependent viability assays, promoter-reporter experiments, and bioluminescence imaging workflows. This scenario-based guide connects formulation, controls, optimization, data interpretation, and supplier selection to practical laboratory decisions.
Lactylation–NSUN2 Axis in PDAC Perineural Invasion
2026-10-01
This study identifies NSUN2 K692 lactylation as a metabolic-to-epitranscriptomic mechanism that promotes perineural invasion in pancreatic ductal adenocarcinoma. By linking lactate accumulation to m5C-dependent stabilization of CDCP1 and STC1 transcripts, the work provides a mechanistic framework for studying tumor–nerve interactions and potential intervention points.
RIPA Lysis Buffer (Medium) for EV Signaling
2026-09-30
RIPA Lysis Buffer (Medium) turns extracellular-vesicle stimulation into reproducible cell and tissue lysates for pathway-focused protein analysis. Its balanced detergent system supports Western blotting and other assays, while careful inhibitor selection and assay-specific optimization help preserve phosphosignals and protein complexes.
NHS-Biotin: Practical Protein Biotinylation
2026-09-30
NHS-Biotin (SKU A8002) is an amine-reactive reagent for attaching biotin to accessible lysine side chains and N-terminal amines on antibodies, proteins, and other biomolecules. It is suited to detection, purification, and selected intracellular labeling workflows, but it is not site-specific and requires control of solvent exposure, buffer composition, reagent hydrolysis, and labeling density.
Gap19 Workflow for Cx43 Hemichannel Studies
2026-09-29
Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap junction communication. This practical guide covers astrocyte ATP-release assays, macrophage inflammation workflows, ischemia models, dosing logic, and troubleshooting.
miR-18a–ALOXE3 Axis in Glioblastoma
2026-09-29
The reference study identifies a miR-18a–ALOXE3 regulatory axis that promotes glioblastoma by weakening p53-SLC7A11-dependent ferroptosis and increasing 12-HETE-driven migration. Its combination of molecular perturbation, lipid mediator analysis, and orthotopic modeling provides a useful framework for connecting lipid metabolism with tumor cell survival and dissemination.
Estradiol–Autophagy Axis in Perimenopausal Aging
2026-09-28
A 2026 Life Sciences study integrates NHANES analysis, network pharmacology, and perimenopausal mouse experiments to examine how declining estradiol relates to cardiovascular, renal, and metabolic vulnerability. Its central contribution is evidence that estrogen receptor activity and downstream autophagy jointly reduce fibrosis across the heart, aorta, and kidneys, while also highlighting important limits for translating hormone treatment into clinical practice.
Fluorescence-Based mRNA Translation Reporter Assays
2026-09-28
This methods chapter describes GFP- and luciferase-based reporter mRNAs for testing how 5′-UTR sequences influence translation. By transfecting synthetic, capped and polyadenylated mRNA directly into cells, the approach helps isolate translation-related effects from several complications of plasmid-based expression.
Hyperthermia–Cisplatin Activates Caspase-8 in Cancer Cells
2026-09-27
A 2024 study finds that hyperthermia combined with cisplatin promotes K63-linked polyubiquitination and accumulation of caspase-8, enhancing both apoptotic and pyroptotic responses in cancer cells. The work links Cullin 3 and p62 to this response and shows why caspase activity measurements are most informative when interpreted alongside genetic and cell-death assays.
EZ Cap™ Firefly Luciferase mRNA: Assay Guide
2026-09-26
EZ Cap™ Firefly Luciferase mRNA is a Cap1-capped reporter transcript designed for luciferase expression in delivery, translation, viability, and imaging workflows. Its specifications support experimental planning, while a cited ssDNA-sensing study provides distinct immune-biology context—not evidence about this reporter mRNA.
Pam3CSK4 TFA: Interpreting TLR1/2 Responses
2026-09-25
Pam3CSK4 TFA is a defined TLR1/2 agonist for probing how innate immune cells respond to bacterial-lipoprotein signals. This article connects controlled receptor stimulation with recent maternal–newborn cytokine findings—and explains what the results can, and cannot, tell researchers about infection risk.
circ_0136666 Drives Gastric Cancer Immune Escape
2026-09-25
Miao et al. identify hsa_circ_0136666 as a gastric cancer-associated circular RNA that promotes tumor growth and immune escape through a miR-375-3p/PRKDC pathway linked to PD-L1 phosphorylation and stability. The study also reports that lipid nanoparticle delivery of siRNA against the circRNA can improve anti-PD-L1 treatment activity in a mouse model, providing a preclinical rationale for targeting this regulatory axis.
Ziprasidone HCl: Making Permeability Data Interpretable
2026-09-24
Ziprasidone HCl connects receptor pharmacology and emerging cancer-metabolism research, but formulation can shape what an assay actually measures. This article examines Caco-2 nanocrystal evidence and practical controls for interpreting permeability and antitumor experiments.
Targeted Fabp4 CRISPRi Improves Obesity Phenotypes
2026-09-24
The study paired adipose-targeting peptide delivery with a nonviral CRISPR interference system to suppress Fabp4 in white adipocytes. In obese mice, this approach was associated with reduced body weight and inflammation, improved hepatic steatosis, and better insulin-resistance phenotypes, while leaving important questions about durability and translation unresolved.
Puromycin aminonucleoside: Reliable Injury Models
2026-09-23
A practical guide to using Puromycin aminonucleoside (SKU A3740) in podocyte injury and nephrotoxicity studies. Learn how to interpret cell-based potency data, plan stocks and controls, and select an experimental workflow without overgeneralizing assay-specific results.